Home > Back to Publisher > Report Information

Therapeutic Peptides in Oncology - Favorable Conditions But Where to Commercialize?

BioSeeker Group AB
May 28, 2009
373 Pages - SKU: BIOS2275865

Abstract Table of Contents Related Reports

The discovery of new cancer therapeutics has seen a significant shift towards biologicals as an alternative to small molecule drugs. Alternative binding peptide molecules, derived from combinatorial scaffold libraries, are now challenging traditional antibodies. This report identifies the competitive terrain for cancer therapeutic peptides to be wide open from a compound perspective and the opportunity for peptide drugs to challenge other biologicals such as antibodies is real and significant.

This report includes defined and up to date development strategies for 92 cancer therapeutic peptide drugs (>170 projects) within the portfolio of 70 investigators, from Ceased to Marketed. In total the report assesses 30 different cancer indications. The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It serves as an external commercial advocate for pharmaceutical companies’ portfolio planning and new product planning by:

Providing you with competitive input to the R&D organization to guide development of early
Assisting you to make informed decisions in selecting cancer indications that are known to
Analyzing, correlating and integrating valuable data sources in order to provide accurate
Providing you with commercial analytic support for due diligence on in-licensing and
Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report will also be an important part of creating and implementing a market development plan for any cancer therapeutic peptide drugs to ensure that the optimal market conditions exist by the time the product is commercialized.

1 Executive Summary
2 About Cancer Highlights
3 Methodologies
4 Table of Contents: 4.1 List of Figures; 4.2 List of Tables
5 Introduction: 5.1 The Scope of this Report; 5.2 The Competitive Advantage and Disadvantage of Peptide Drugs; 5.3 Definitions; 5.4 Abbreviations
6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment: 6.2 The Cancer Genome Project and Peptide Drug Targets; 6.3 Structure-based Drug Design of Anti-Cancer Peptides is Stimulated by Available Structure; Data on Biological Targets; 6.4 Target-Target Interactions among Identified Peptide Targets; 6.5 The Drug-Target Interactome; 6.6 Protein Expression Levels of Identified Drug Targets of Anti-Cancer Peptide Drugs; 6.7 Pathway Analysis of Anti-Cancer Peptide Drug Targets
7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug: 7.1 Marketed: New and Unique Target Profiles in the Cancer Therapeutic Peptide Pipeline; 7.2 Phase III Clinical Development: New and Unique Target Profiles in the Cancer; Therapeutic Peptide Pipeline; 7.3 Phase II Clinical Development: New and Unique Target Profiles in the Cancer Therapeutic; Peptide Pipeline; 7.4 Phase I Clinical Development: New and Unique Target Profiles in the Cancer Therapeutic; Peptide Pipeline; 7.5 Preclinical Development: New and Unique Target Profiles in the Cancer Therapeutic; Peptide Pipeline; 7.6 Development Stage Outline of All Cancer Therapeutic Peptides by Target Profiles
8 Selecting Cancer Indication for Therapeutic Peptides: 8.1 Acute Myelogenous Leukemia; 8.2 Benign Prostatic Hyperplasia; 8.3 Bladder Cancer; 8.4 Brain Cancer; 8.5 Breast Cancer; 8.6 Carcinoid; 8.7 Chronic Myelogenous Leukemia; 8.8 Colorectal Cancer; 8.9 Gastrointestinal Cancer (general); 8.10 Gastrointestinal Stomach Cancer; 8.11 Head and Neck Cancer; 8.12 Liver Cancer; 8.13 Lung Cancer (general); 8.14 Lymphoma (general); 8.15 Melanoma; 8.16 Mesothelioma; 8.17 Myelodysplastic Syndrome; 8.18 Myeloma; 8.19 Myoma; 8.20 Neuroblastoma; 8.21 non-Hodgkin's Lymphoma; 8.22 Non-small Cell Lung Cancer; 8.23 Ovarian Cancer; 8.24 Pancreatic Cancer; 8.25 Prostate Cancer; 8.26 Renal Cancer; 8.27 Sarcoma (general); 8.28 Small Cell Lung Cancer; 8.29 Soft Tissue Sarcoma; 8.30 Unspecified Cancer Indication
9 Portfolio Planning: Competitive Benchmarking of Cancer Therapeutic Peptide Pipeline by Investigator: 9.1 Abbott; 9.2 Acceleron Pharma; 9.3 Aeterna Zentaris; 9.4 Affymax; 9.5 Ambrilia Biopharma; 9.6 AplaGen Biopharmaceuticals; 9.7 ApopLogic Pharmaceuticals; 9.8 Apthera; 9.9 Ardana; 9.10 Attenuon; 9.11 AVI BioPharma; 9.12 Baxter International; 9.13 BioAlliance Pharma; 9.14 Biokine Therapeutics; 9.15 CanBas; 9.16 Cancer Innovations; 9.17 Cancer Research Technology; 9.18 Celecure; 9.19 Celldex Therapeutics; 9.20 Chemokine Therapeutics; 9.21 Compugen; 9.22 Cyclacel; 9.23 Dendreon; 9.24 DOR BioPharma; 9.25 Enkam Pharmaceuticals; 9.26 EntreMed; 9.27 GlaxoSmithKline; 9.28 GP Pharm; 9.29 ImmunoCellular Therapeutics; 9.30 Immunotope; 9.31 ImmuPharma; 9.32 Indevus; 9.33 Innovive; 9.34 Johnson & Johnson; 9.35 Mediolanum; 9.36 MolMed; 9.37 Nektar Therapeutics; 9.38 Nemod Biotherapeutics; 9.39 Nidus Laboratories; 9.40 Norwood Abbey; 9.41 Novartis; 9.42 OncoTherapy Science; 9.43 Oncothyreon; 9.44 Pepscan Systems; 9.45 PharmaGap; 9.46 Pharmexa; 9.47 QLT; 9.48 Raptor Pharmaceutical; 9.49 Receptor BioLogix; 9.50 SciClone Pharmaceuticals; 9.51 Shire; 9.52 Spectrum Pharmaceuticals; 9.53 Thallion Pharmaceuticals; 9.54 Therion Biologics; 9.55 Theryte; 9.56 Tigris Pharmaceuticals; 9.57 Unigene; 9.58 United Biomedical; 9.59 Vaxil BioTherapeutics; 9.60 Vaxon Biotech; 9.61 Voyager Pharmaceutical; 9.62 Xigen; 9.63 Zelos Therapeutics; 9.64 Zensun; 9.65 Non-Industrial sources
10 Disclaimer
11 Drug Index
12 Company Index
4.1 List of Figures: Figure 1: Overall Breakdown of the Included Cancer Therapeutic Peptide Pipeline by Cancer Indication and; Stage of Development; Figure 2: Visualization of Target-Target Interactions Among Peptide Drug Targets; Figure 3: The Drug-Protein Interactome of Peptide Drugs; 4.2 List of Tables; Table 1: Competitive Pressure Force Among Cancer Therapeutic Peptides; Table 2: Overview of Drug Target Profile Themes; Table 3: Drug Targets of Peptide Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the; Cancer Gene Census; Table 4: Identity of Peptide Drug Targets with Available Biological Structures; Table 5: Number of Target-Target Interactions among Peptide Drug Targets; Table 6: Drug-Protein Interactome Clusters; Table 7: Peptide Drug Targets with Available Protein Expression Profiles; Table 8: Pathway Summary; Table 9: Peptide Drug Targets without any Identified Assigned Pathways; Table 10: Pathway Profile According to BioCarta of Peptide Drug Targets; Table 11: Pathway Profile According to KEGG of Peptide Drug Targets; Table 12: Pathway Profile According to NetPath of Peptide Drug Targets; Table 13: Number of Drug Target Profiles of Peptide Drugs by the Highest Developmental Stage and; Uniqueness; Table 14: Terminally Ceased Drug Target Profiles of Cancer Therapeutic Peptides; Table 15: Top 5 Competitive Peptide Drug Target Profiles; Table 16 New and Unique Target Profiles of Peptide Drugs on the Market; Table 17: New and Unique Target Profiles of Peptide Drugs in Phase III Clinical Development; Table 18: New and Unique Target Profiles of Peptide Drugs in Phase II Clinical Development; Table 19 New and Unique Target Profiles of Peptide Drugs in Phase I Clinical Development; Table 20: New and Unique Target Profiles of Peptide Drugs in Preclinical Development; Table 21: The Progression, Maturity and Competitive Comparison of Cancer Therapeutic Peptide Target Profiles; in Development; Table 22: Competitive Summary of Peptide Drugs by Cancer Indication; Table 23: Drug Target Profiles of Peptides for the Treatment of Acute Myelogenous Leukemia According to; Developmental Stage of Peptide; Table 24: Drug Target Profiles of Peptides for the Treatment of Benign Prostatic Hyperplasia According to; Developmental Stage of Peptide; Table 25: Drug Target Profiles of Peptides for the Treatment of Bladder Cancer According to Developmental; Stage of Peptide; Table 26: Drug Target Profiles of Peptides for the Treatment of Brain Cancer According to Developmental Stage; of Peptide; Table 27: Drug Target Profiles of Peptides for the Treatment of Breast Cancer According to Developmental; Stage of Peptide; Table 28: Drug Target Profiles of Peptides for the Treatment of Carcinoid According to Developmental Stage of; Peptide; Table 29: Drug Target Profiles of Peptides for the Treatment of Chronic Myelogenous Leukemia According to; Developmental Stage of Peptide; Table 30: Drug Target Profiles of Peptides for the Treatment of Colorectal Cancer According to Developmental; Stage of Peptide; Table 31: Drug Target Profiles of Peptides for the Treatment of Gastrointestinal Cancer (general) According to; Developmental Stage of Peptide; Table 32: Drug Target Profiles of Peptides for the Treatment of Gastrointestinal Stomach Cancer According to; Developmental Stage of Peptide; Table 33: Drug Target Profiles of Peptides for the Treatment of Head and Neck Cancer According to; Developmental Stage of Peptide; Table 34: Drug Target Profiles of Peptides for the Treatment of Liver Cancer According to Developmental Stage; of Peptide; Table 35: Drug Target Profiles of Peptides for the Treatment of Lung Cancer (general) According to; Developmental Stage of Peptide; Table 36: Drug Target Profiles of Peptides for the Treatment of Lymphoma (general) According to; Developmental Stage of Peptide; Table 37: Drug Target Profiles of Peptides for the Treatment of Melanoma According to Developmental Stage; of Peptide; Table 38: Drug Target Profiles of Peptides for the Treatment of Mesothelioma According to Developmental; Stage of Peptide; Table 39: Drug Target Profiles of Peptides for the Treatment of Myelodysplastic Syndrome According to; Developmental Stage of Peptide; 4 Therapeutic Peptides in Oncology -Favorable Conditions But Where to; Commercialize?; 16 Cancer Highlights No 8 Vol 8 2009| BioSeeker Group AB ©; Table 40: Drug Target Profiles of Peptides for the Treatment of Myeloma According to Developmental Stage of; Peptide; Table 41: Drug Target Profiles of Peptides for the Treatment of Myoma According to Developmental Stage of; Peptide; Table 42: Drug Target Profiles of Peptides for the Treatment of Neuroblastoma According to Developmental; Stage of Peptide; Table 43: Drug Target Profiles of Peptides for the Treatment of non-Hodgkin's Lymphoma According to; Developmental Stage of Peptide; Table 44: Drug Target Profiles of Peptides for the Treatment of Non-small Cell Lung Cancer According to; Developmental Stage of Peptide; Table 45: Drug Target Profiles of Peptides for the Treatment of Ovarian Cancer According to Developmental; Stage of Peptide; Table 46: Drug Target Profiles of Peptides for the Treatment of Pancreatic Cancer According to Developmental; Stage of Peptide; Table 47: Drug Target Profiles of Peptides for the Treatment of Prostate Cancer According to Developmental; Stage of Peptide; Table 48: Drug Target Profiles of Peptides for the Treatment of Renal Cancer According to Developmental Stage; of Peptide; Table 49: Drug Target Profiles of Peptides for the Treatment of Sarcoma (general) According to Developmental; Stage of Peptide; Table 50: Drug Target Profiles of Peptides for the Treatment of Small Cell Lung Cancer According to; Developmental Stage of Peptide; Table 51: Drug Target Profiles of Peptides for the Treatment of Soft Tissue Sarcoma According to; Developmental Stage of Peptide; Table 52: Drug Target Profiles of Peptides for the Treatment of Not Specified Cancer Indication According to; Developmental Stage of Peptide; Table 53: Abbott's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out; Table 54: Acceleron Pharma's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-; Out; Table 55: Aeterna Zentaris’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out; Table 56: Affymax's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out; Table 57: Ambrilia Biopharma's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive; Fall-Out; Table 58: AplaGen Biopharmaceuticals’ Included Cancer Therapeutic Peptide Pipeline Composition and; Competitive Fall-Out; Table of Contents; BioSeeker Group AB © 2009 | www.bioseeker.com; Table 59: ApopLogic Pharmaceuticals’ Included Cancer Therapeutic Peptide Pipeline Composition and; Competitive Fall-Out; Table 60: Apthera's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out; Table 61: Ardana's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out; Table 62: Attenuon's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out; Table 63: AVI BioPharma's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out; Table 64: Baxter International's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive; Fall-Out; Table 65: BioAlliance Pharma's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-; Out; Table 66: Biokine Therapeutics’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive; Fall-Out; Table 67: CanBas’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out; Table 68: Cancer Innovations’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-; Out; Table 69: Cancer Research Technology's Included Cancer Therapeutic Peptide Pipeline Composition and; Competitive Fall-Out; Table 70: Celecure's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out; Table 71: Celldex Therapeutics’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-; Out; Table 72: Chemokine Therapeutics’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive; Fall-Out; Table 73: Compugen's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out .; Table 74: Cyclacel's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out; Table 75: Dendreon's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out; Table 76: DOR BioPharma's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-; Out; Table 77: Enkam Pharmaceuticals’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive; Fall-Out; Table 78: EntreMed's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out; Table 79: GlaxoSmithKline's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-; Out; Table 80: GP Pharm's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out; Table 81: ImmunoCellular Therapeutics’ Included Cancer Therapeutic Peptide Pipeline Composition and; Competitive Fall-Out; 4 Therapeutic Peptides in Oncology -Favorable Conditions But Where to; Commercialize?; 18 Cancer Highlights No 8 Vol 8 2009| BioSeeker Group AB ©; Table 82: Immunotope's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out; Table 83: ImmuPharma's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out; Table 84: Indevus’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out; Table 85: Innovive's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out; Table 86: Johnson & Johnson's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-; Out; Table 87: Mediolanum's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out; Table 88: MolMed's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out; Table 89: Nektar Therapeutics’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-; Out; Table 90: Nemod Biotherapeutics’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive; Fall-Out; Table 91: Nidus Laboratories’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-; Out; Table 92: Norwood Abbey's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out; Table 93: Novartis’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out; Table 94: OncoTherapy Science's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive; Fall-Out; Table 95: Oncothyreon's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out; Table 96: Pepscan Systems’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out; Table 97: PharmaGap's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out; Table 98: Pharmexa's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out ..; Table 99: QLT's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out; Table 100: Raptor Pharmaceutical's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive; Fall-Out; Table 101: Receptor BioLogix's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-; Out; Table 102: SciClone Pharmaceuticals’ Included Cancer Therapeutic Peptide Pipeline Composition and; Competitive Fall-Out; Table 103: Shire's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out; Table of Contents; BioSeeker Group AB © 2009 | www.bioseeker.com; Table 104: Spectrum Pharmaceuticals’ Included Cancer Therapeutic Peptide Pipeline Composition and; Competitive Fall-Out; Table 105: Thallion Pharmaceuticals’ Included Cancer Therapeutic Peptide Pipeline Composition and; Competitive Fall-Out; Table 106: Therion Biologics’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-; Out; Table 107: Theryte's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out; Table 108: Tigris Pharmaceuticals’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive; Fall-Out; Table 109: Unigene's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out; Table 110: United Biomedical's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-; Out; Table 111: Vaxil BioTherapeutics’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive; Fall-Out; Table 112: Vaxon Biotech's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out; Table 113: Voyager Pharmaceutical's Included Cancer Therapeutic Peptide Pipeline Composition and; Competitive Fall-Out; Table 114: Xigen's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out; Table 115: Zelos Therapeutics’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-; Out; Table 116: Zensun's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out; Table 117: Non-industrial source's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive; Fall-Out

Therapeutic Peptides in Oncology - Favorable Conditions But Where to Commercialize?

Share this report

Other tasks

Research Assistance

Related Markets

Oncology/Hematology Reports

Free Alert Me service